RTTNews | Mar 23, 2021 09:14AM EDT

09:13 Tuesday, March 23, 2021 (RTTNews.com) - CureVac N.V. (CVAC) published preclinical data showing that their COVID-19 vaccine candidate, CVnCoV, protects against challenge infections with the SARS-CoV-2 Variant of Concern B.1.351 or the South African variant, and a strain of the original SARS-CoV-2 B1 lineage in a transgenic mouse model.

Igor Splawski, Chief Scientific Officer of CureVac, said: "To our knowledge, this is the first challenge study in a human ACE2 transgenic mouse model of severe disease that shows complete protection against one of the most threatening virus variants."

Read the original article on RTTNews ( https://www.rttnews.com/3179519/curevac-cvncov-vaccine-candidate-protects-against-south-african-variant-in-preclinical-study.aspx)

For comments and feedback: contact editorial@rttnews.com

Copyright(c) 2021 RTTNews.com All Rights Reserved